Geron Earnings Reports

Geron Corporation reported Q4 2024 financial results, achieving $47.5 million in RYTELO net product revenue and ending the year with a strong cash position. The company expects to reach profitability without additional financing if current sales and operating expense expectations are met. Continued progress in development efforts for relapsed/refractory myelofibrosis could potentially double commercial opportunity.

Geron Corporation reported financial results for the third quarter of 2024, highlighted by $28.2 million in RYTELO net product revenue in its first full quarter of sales. The company also completed synthetic royalty and debt financings, receiving $250 million in gross proceeds.

Geron Corporation reported a net loss of $67.4 million, or $0.10 per share, for the second quarter of 2024. The company launched RYTELO commercially in the U.S. in June 2024. Total product revenue, net for the quarter was approximately $780,000.

Geron reported a net loss of $55.4 million, or $0.09 per share, for the first quarter of 2024. As of March 31, 2024, the Company had approximately $465 million in cash and marketable securities.

Geron Corporation reported its Q4 and Full Year 2023 financial results, highlighting progress with imetelstat and preparation for potential commercialization. The company's financial resources are projected to fund operations into the third quarter of 2025, with $378.1 million in cash, cash equivalents, and marketable securities as of December 31, 2023.

Geron Corporation reported $381.9 million in cash, cash equivalents, and marketable securities as of September 30, 2023. Revenues for the quarter were $164,000, and total operating expenses were $47.8 million. The company projects its financial resources will be sufficient to fund operating requirements through the end of Q3 2025.

Geron Corporation reported business highlights and financial results for the second quarter of 2023, highlighted by the submission of a New Drug Application (NDA) to the FDA for imetelstat in lower risk myelodysplastic syndromes (MDS). The company's financial resources of approximately $400 million are expected to fund a potential successful launch and support the first year of launch.

Geron reported a net loss of $38.1 million, or $0.07 per share, for the first quarter of 2023. As of March 31, 2023, the Company had $409.2 million in cash and marketable securities and believes it has sufficient resources to fund operating requirements through the end of the third quarter of 2025.

Geron Corporation reported a net loss of $42.6 million for the fourth quarter of 2022 and ended the year with $173.1 million in cash and marketable securities. The company is focused on completing regulatory submissions for imetelstat in lower risk MDS and preparing for its potential commercial launch in the U.S.

Geron Corporation reported a net loss of $41.1 million, or $0.10 per share, for the third quarter of 2022. As of September 30, 2022, the Company had approximately $195 million in cash and marketable securities, which is expected to support operations through the middle of 2024.

Geron Corporation reported a net loss of $28.1 million, or $0.07 per share, for the second quarter of 2022. As of June 30, 2022, the Company had approximately $220 million in cash and marketable securities. The company believes current and projected financial resources will be sufficient to fund operations until the middle of 2024.

Geron Corporation reported a net loss of $30.1 million, or $0.09 per share, for the first quarter of 2022. As of March 31, 2022, the Company had $178.0 million in cash and marketable securities.

Geron Corporation reported a net loss of $32.0 million for the fourth quarter of 2021, compared to a net loss of $23.8 million for the same period in 2020. The company ended the year with $212.7 million in cash and marketable securities, expected to fund operations through Q1 2023. Key milestones include anticipated top-line results from the IMerge Phase 3 trial in early January 2023 and a planned interim analysis from the IMpactMF trial in 2024.

Geron Corporation reported its Q3 2021 financial results, including a net loss of $26.7 million, and summarized key highlights from its Investor Event, where the company emphasized the disease-modifying activity of Imetelstat and its potential in treating hematologic malignancies.

Geron Corporation reported a net loss of $29.6 million, or $0.09 per share, for the second quarter of 2021. As of June 30, 2021, the Company had $239.1 million in cash and marketable securities, expected to fund operations through the end of the first quarter of 2023. Enrollment in IMerge Phase 3 reached 91%, with top-line results expected in the first quarter of 2023.

Geron Corporation reported a net loss of $27.8 million, or $0.09 per share, for the first quarter of 2021. As of March 31, 2021, the Company had $244.7 million in cash and marketable securities, expected to fund operations until the end of 2022.

Geron Corporation reported a net loss of $23.8 million for the fourth quarter of 2020. The company ended the year with $260 million in cash and marketable securities, expected to fund operations until the end of 2022.

Geron Corporation reported a net loss of $19.7 million, or $0.06 per share, for the third quarter of 2020. As of September 30, 2020, the company had approximately $274 million in cash and investments, which is expected to be sufficient for operations until the end of 2022.

Geron Corporation reported a net loss of $15.8 million, or $0.06 per share, for the second quarter of 2020. The company is focusing on the development of Imetelstat and expects to fund its development plans into the second half of 2022.

Geron reported a net loss of $16.4 million, or $0.08 per share, for the first quarter of 2020, compared to a net loss of $10.1 million, or $0.05 per share, for the comparable 2019 period. As of March 31, 2020, Geron had approximately $133 million in cash, cash equivalents, and current and non-current marketable securities.

Geron Corporation reported a net loss of $29.1 million, or $0.15 per share, for the fourth quarter of 2019. The company ended the year with $159.2 million in cash and marketable securities.